SCHEMBL3369247

SCHEMBL3369247

CCO[C@@H](Cc1ccc(OCc2csc(-c3ccc(F)c(Cl)c3)n2)cc1C)C(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.41
PPARG P37231 6/20 0.41
TP53 P04637 4/20 0.39
EIF4E P06730 1/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
PPARD Q03181 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
ALOX5 P09917 1/20 0.36
SCN9A Q15858 1/20 0.36
PTPRC P08575 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPA Q15257 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6527178 0.92 EIF4E (0.41) PPARAPPARGTP53EIF4ELMNA
SCHEMBL3369621 0.92 EIF4E (0.41) PPARAPPARGTP53EIF4ELMNA
SCHEMBL3370967 0.91 PPARG (0.49) PPARAPPARGTP53LMNATHRB
SCHEMBL3371638 0.87 PPARG (0.48) PPARAPPARGTP53LMNATHRB
SCHEMBL3371632 0.87 PPARG (0.48) PPARAPPARGTP53LMNATHRB
SCHEMBL3375211 0.86 PPARG (0.46) PPARAPPARGTP53LMNAPPARD
SCHEMBL3373823 0.86 PPARA (0.51) PPARAPPARGTP53LMNAPPARD
SCHEMBL3368946 0.85 PPARG (0.49) PPARAPPARGTP53LMNATHRB
SCHEMBL3374207 0.84 PPARA (0.49) PPARAPPARGTP53LMNATHRB
SCHEMBL3371470 0.84 PPARA (0.39) PPARAPPARGTP53EIF4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR PPARA 287/4885PPARG 181/4885TP53 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.